At 9.3% CAGR, the Asia Pacific Glioma Treatment Market is projected to be worth US$ 1,538.88 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific glioma treatment market was valued at US$ 754.97 million in 2022 and is expected to reach US$ 1,538.88 million by 2030, registering a CAGR of 9.3% from 2022 to 2030. Increase in prevalence of high-grade glioma and increasing opportunities in emerging economies are among the critical factors attributed to the Asia Pacific glioma treatment market expansion.

High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients' lives due to their location within the brain and ability to disrupt critical neurological functions.

The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.

On the contrary, the high cost of diagnosis hampers the Asia Pacific glioma treatment market.

Based on disease, the Asia Pacific glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held 71.1% share of Asia Pacific glioma treatment market in 2022, amassing US$ 536.53 million. It is projected to garner US$ 1,123.67 million by 2030 to expand at 9.7% CAGR during 2022–2030.

Based on treatment type, the Asia Pacific glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held 46.6% share of Asia Pacific glioma treatment market in 2022, amassing US$ 351.45 million. It is projected to garner US$ 751.39 million by 2030 to expand at 10.0% CAGR during 2022–2030.

Based on grade, the Asia Pacific glioma treatment market is segmented into low grade and high grade. The high grade segment held 80.7% share of Asia Pacific glioma treatment market in 2022, amassing US$ 609.53 million. It is projected to garner US$ 1,266.88 million by 2030 to expand at 9.6% CAGR during 2022–2030.

Based on end user, the Asia Pacific glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held 78.3% share of Asia Pacific glioma treatment market in 2022, amassing US$ 590.94 million. It is projected to garner US$ 1,213.87 million by 2030 to expand at 9.4% CAGR during 2022–2030.

Based on country, the Asia Pacific glioma treatment market has been categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.0% share of Asia Pacific glioma treatment market in 2022. It was assessed at US$ 234.24 million in 2022 and is likely to hit US$ 495.74 million by 2030, exhibiting a CAGR of 9.8% during 2022–2030.      

Key players operating in the Asia Pacific glioma treatment market are Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com